** Biotech firm Beam Therapeutics' BEAM.O shares rise 5.6% to $23.43 premarket
** BEAM said late on Thursday that the U.S. FDA has cleared its marketing application for its experimental drug, BEAM-302, to treat a type of genetic disorder called alpha-1 antitrypsin deficiency (AATD)
** AATD is a rare genetic disorder associated with a considerable burden of lung and liver disease, and for which there are no currently approved curative treatments, co says
** Brokerage BofA Global Research says data from the drug's clinical trial, though early-stage, is "potentially practice-changing"
** Brokerage remains positive on the market for AATD with more than $5 billion unadjusted peak sales
** Thirteen of 17 brokerages rate the stock "buy" or higher, 4 "hold"
** As of last close, BEAM has fallen ~35% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。